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KEY POINTS
 Not all patients with early stage cutaneous T-cell lymphoma (CTCL) require treatment.
 Topical therapies are effective in treatment and management of early stage CTCL and as adjuvant
treatment with systemic therapy for more aggressive disease.
 Topical therapies have been most extensively studied for use in mycosis fungoides. Further studies
are needed to evaluate their efficacy in other forms of CTCL.INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) are an
uncommon group of cutaneous lymphoprolifera-
tive disorders, characterized by skin infiltration
with malignant mature T cells. Mycosis fungoides
(MF) and its leukemic variant, Se´zary syndrome
(SS), are the most common types of CTCL. Given
their prevalence, most topical therapies for CTCL
are primarily those used, and whose clinical
efficacy has been studied, in MF/SS. These thera-
peutic options are numerous and varied, with treat-
ment often based on physician experience, patient
preference, and/or prognostic factors (ie, staging,
histology).1 The National Comprehensive Cancer
Network (NCCN) guidelines on MF/SS provide an
overall framework for treatment, but, with so
many treatment alternatives, determination of
regimen efficacy and timing of regimen transitions
can be difficult. In 2011, the International Society
for Cutaneous Lymphomas, the United States
Cutaneous Lymphoma Consortium, and the Euro-
pean Organization for Research and Treatment of
Cancer Cutaneous Lymphoma Taskforce released
aconsensus statement detailing theendpoints and
response criteria of therapy for MF/SS.2,3 The goal
of this statement was to provide a standardizedDepartment of Dermatology, University of Minnesota,
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more consistent research protocols. This article
provides a uniform resource for choosing topical
therapies for MF/SS. It summarizes the currently
available skin-directed therapies forMF/SS and re-
views the response rates using the Cutaneous
Lymphoma Taskforce consensus statement.
TOPICAL THERAPIES
At present, there is no widely acknowledged cure
for MF/SS, with death from disease ranging from
10% to 15%,4 to up to 43%.1 However, these
adverse survival outcomes primarily apply to those
patients with MF with more advanced disease.
Most patients with early stage MF (stages IA, IB,
and IIA) generally have favorable outcomes.
Research studies in stage IA patients showed no
difference in survival in those undergoing treat-
ment compared with age-matched and sex-
matched controls,4,5 whereas patients with stage
IB and IIA had an increased relative risk of 2.2.1,6
The overall goal of therapy for MF/SS is to improve
quality of life (ie, symptomatic relief, improve
appearance) and delay or prevent disease pro-
gression. In early stage MF, there are no current
data to show that more aggressive systemic516 Delaware Street S.E., Mail Code 98, Phillips-
455, USA
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Nguyen & Bohjanen684regimens, including chemotherapy, modify overall
survival, and they may be associated with greater
morbidity and complications.7 Thus, treatment
of early stage MF tends to focus first on skin-
directed therapy (SDT).
Emollients
Emollients have long been studied in the repair of
compromised skin barrier.8 Inflammatory skin con-
ditions, likeMF/SS, lead todisruptionof theskinbar-
rier, and often result in dry, scaly skin secondary to
transepidermal water loss (TEWL). Emollients, or
moisturizers, contain occlusive properties that pre-
vent TEWL, and/or humectants that help to absorb
water from the surrounding environment, increasing
the water-holding capacity of the stratum cor-
neum.8,9 The most common of these humectants
is glycerin, which has been shown to decrease cor-
neocyte loss from the superficial epidermis, and
alter the lipid barrier to decrease TEWL.10,11
To control symptoms of pruritus or scale, the
use of simple emollients can be helpful.
At our site, we recommend application of emol-
lients twice daily in the form of a cream. Although
ointments are more occlusive and better moistur-
izers, patient compliance is often an issue given
the greasy quality. In addition, the first andonly ran-
domized, placebo-controlled trial of topical emol-
lient therapy for MF only evaluated the use of a
cream emollient. This study showed that 24% of
46 patients with patch-stage or plaque-stage MF
receiving a placebo of simple emollient cream
achieved a partial response (PR).12 Regardless,
this high placebo response suggests an important
adjunctive role for simple emollients in the treat-
ment of MF.
Corticosteroids
Topical corticosteroids function through the
binding and activation of intracytoplasmic gluco-
corticoid receptors. In a broad sense, they act
through both antiinflammatory and antiproliferative
mechanisms. They seem to affect nearly every
stage of the inflammatory response. By stabi-
lizing the cell and lysosomal membranes, they
inhibit phagocytosis, and decrease monocytic
and lymphocytic activity. They decrease chemical
mediators such as interleukin (IL)-1, IL-2, inter-
feron-gamma, tumor necrosis factor, and
granulocyte-monocyte colony–stimulating factor.13
Topical corticosteroids further lead to a reduction in
mitotic activity and cause apoptosis of malignant
cells.14 They also reduce epidermal thickness,
dermal water content, and collagen and elastic
fiber production, which explains their common
cutaneous side effects (further discussed later).13The pharmacokinetics of topical corticosteroids
are complex and depend on several factors,
including structure and concentration of the
drug, the vehicle, and the condition of the skin
on which it is being applied. In addition, the skin
can act as a reservoir for the applied drug, allowing
for storage for 2 to 14 days in nonoccluded and
occluded skin, respectively.14,15 With so many
disparate variables, it is often difficult to assess
the pharmacokinetics and pharmacodynamics of
topical corticosteroids, and their efficacy is
instead assessed by means of their potency as
measured through the Stoughton vasoconstriction
assay.13
Although topical corticosteroids have been used
since the 1960s for treatment of MF,16,17 evidence
for their use is still scarce. The largest prospective
study to date on topical corticosteroid use in MF is
that of Zackheim and colleagues.18 Seventy-nine
patients with skin stage T1 and T2MFwere treated
(all of the T1 patients and 68% of the T2 patients)
with class 1 topical steroids. Of the 79 patients,
94% of T1 and 82% of T2 patients showed at least
a PR to treatment. A complete response (CR) was
seen in 63% of T1 and 25% of T2 patients. Once
therapy was stopped, only 37% of T1 and 18%
of T2 patients retained complete remission. In a
2003 follow-up report, Zackheim19 noted con-
tinued rates of PR to CR in more than 200 cases
ranging from 80% to 90% in T1 and T2 patients,
respectively. Lower strength topical steroids,
such as low-strength to midstrength concentra-
tions of fluocinolone acetonide 0.025% to 0.1%
creams, have also been helpful, with response
rates of 67% to 89%,16,17 and can provide symp-
tomatic relief of scale and pruritus.20 However, for
scale and pruritus, patients were treated either un-
der occlusion with saran wrap or with wet wraps:
these can be time consuming and burdensome
processes for patients when used long term.
Common cutaneous side effects of topical
corticosteroids include atrophy, striae, purpura,
hypopigmentation, telangiectasias, acne or follicu-
litis, and perioral dermatitis.13,21 Other than striae,
which are permanent, most of these side effects,
tend to resolve over 1 to 4 weeks with cessation
of the drug.13 In addition, allergic contact derma-
titis may occur and Cushing syndrome, hypergly-
cemia, and unmasking of latent diabetes mellitus
have been reported from systemic absorption of
topical corticosteroids. After 2 weeks of continued
use, almost 20% of patients using topical clobeta-
sol for psoriasis had hypothalamus-pituitary-
adrenal (HPA) axis suppression as defined by a
serum cortisol level of 18 mg/dL or less 30 minutes
after cosyntropin stimulation.22 Recovery of HPA
axis function is generally prompt and complete
Skin-Directed Therapies in CTCL 685on discontinuation of topical corticosteroids. It has
therefore been suggested by the US Food and
Drug Administration (FDA) that, when using topical
clobetasol, no more than 50 g/wk for 2 consecu-
tive weeks should be used given the concern for
adrenal suppression. However, despite twice-
daily application of topical clobetasol for months,
sometimes under occlusion, none of the more
than 200 patients with CTCL treated by Zackheim
showed clinical symptoms of adrenal insuffi-
ciency,19,23 and there have been few documented
cases of adrenal insufficiency.24,25 Given that
formal HPA axis suppression testing is rarely
performed, further studies need to be conducted
to evaluate the efficacy and safety of various
potencies of topical corticosteroids as currently
used in treating MF/SS.
Frequency and choice of topical corticosteroid
application for treatment of MF/SS are not stan-
dardized. Although research has shown that
once-daily application may be just as effective as
twice-daily application of topical steroids,26 cur-
rent data on MF treatment are based on twice-
daily application.16–18 Alternative or additional
therapies should be considered if appropriate
response is not obtained by 3 months.
We recommend lesional application of clobeta-
sol 0.05% cream twice daily as the initial treatment
of patients with early stage MF to all involved
lesions, including those on the face, axillae, and
groin. Although clobetasol ointment can also be
considered if cream formulation is not adequate,
we recommend initiation with a cream-based
vehicle, because this is generally more tolerable
to the patient. We base our recommendation for
topical clobetasol cream use on the 1998 study
by Zackheim.19 Other practitioners frequently
incorporate 1-week breaks in the long-term treat-
ment with potent topical steroids in an attempt to
reduce the potential for side effects, and may
use lower-potency steroids on the face, axillae,
or groin. Whether the outcome and side effects
are significantly different with a class I versus class
II to IV topical corticosteroid in MF, stratified
by patch or plaque type lesions, is yet to be
determined.TOPICAL CHEMOTHERAPEUTICS
Mechlorethamine
More colloquially known as nitrogen mustard,
mechlorethamine (Mustargen) functions in vitro
as an alkylating agent. Its high reactivity to DNA
results in alkyl group donation to DNA leading to
cell function disruption and, subsequently, through
an unclear mechanism, apoptosis.27 Despite being
the most studied of the topical therapies for MFand in use for MF since as early as 1946,28 nitro-
gen mustard’s mechanism of action in cutaneous
application is unknown, especially because it
does not seem to have any significant systemic
absorption.27,29,30 It is has been suggested that
it may also interact through an immune-mediated
response via the epidermal–Langerhans cell–T-
cell axis.29,31
Various vehicles for delivery of topical mechlor-
ethamine have been used in treating MF, com-
pounded into formulations of aqueous, ointment,
and more recently, an FDA-approved gel for-
mulation.30,32 Mechlorethamine breaks down
quickly in water, making preparations of topical
formulations difficult, because the only vehicle
completely void of water is an ointment.
Clinical response to aqueous and ointment
preparations of mechlorethamine have varied in
retrospective studies in the literature (Table 1).
Most of these studies evaluated efficacy of
aqueous preparations of nitrogen mustard in
MF.33–35 In 1982, Hamminga and colleagues33 re-
ported on a retrospective study of 42 patients with
MF, including 10 patients with tumor-stage MF,
who were treated with either total-body aqueous
mechlorethamine or total-body (skin) electron
beam irradiation (TSEB) (2800–3000 rad). Of the
patients with early stage MF treated with TSEB,
100% had an initial CR compared with the 82%
treated with aqueous mechlorethamine. Ten of
18 patients (including tumor-stage MF) who had
CR to TSEB radiation developed a relapse within
4 to 16 months. In comparison, all patients treated
with topical mechlorethamine remained in remis-
sion, with maintenance mechlorethamine at a
frequency of once weekly over a median follow-
up period of 41 months. Further retrospective
studies have revealed CR rates of 76.6% to 80%
in T1 or 51.6% to 68% in T2 patients treated with
aqueous preparations, but did not document
how soon before initiation of aqueous mechloreth-
amine patients had discontinued other therapies
or whether they had even received other therapies,
including emollients, before or concurrently.34,35
Another retrospective study completed in 2013 is
also not included in Table 1, because more than
98% of patients treated with aqueous mechloreth-
amine also received various adjunctive therapies,
making interpretation of the clinical response to
mechlorethamine difficult.36
There has been 1 large report of clinical response
inMF toointment preparation of nitrogenmustard.31
Two articles related to this subject are not included
in Table 1 because these patients were included in
the 2003 retrospective report by Kim and col-
leagues.31,37,38 In 2003, Kim and colleagues evalu-
ated a total of 195 patients with stage T1 or T2
Table 1
Clinical response to topical mechlorethamine as initial therapy
Study, Year
Vehicle and
Concentration (mg/mL)
T1 T2
Additional Notes, Including Stage of Patients and
Initial TherapyN CR PR OR NR N CR PR OR NR
Hamminga
et al,33 1982
A, 0.25 8 100 0 100 0 9 66.7 33.3 100 0 Unclear what percentage had NM as initial therapy
Ramsay et al,34
1988
A, 0.17 40 67.3 — — — 67 40.3 — — — Percentage achieving CR after 1 y of therapy. This
percentage may be underestimated because these
numbers do not exclude T3 patients
Vonderheid
et al,35 1989
A, 0.17–0.50 89 80 — — — 66 68 — — — Stage IIA also evaluated but not separated by T stage.
Unclear what percentage had NM as initial therapy
Kim et al,31 2003 O/A, 0.1–0.2 107 65 28 93 7 88 34 38 72 28 Results not separated by vehicle
Lessin et al,30 2013 — No Delineation Between Staging —
O, 0.20 95 14.7 44.2 58.9 41.1 — In the efficacy-evaluable population as measured by
CAILS, patients were either stage IA or IBG, 0.20 90 18.9 57.8 76.7 23.3
T1 tumor stage has less than 10% body surface area involvement; T2 has greater than or equal to 10% body surface area involvement. PR represents greater than or equal to 50%
improvement.
Abbreviations: A, aqueous; BSA, body surface area; CAILS, Composite Assessment of Index Lesion Severity; Conc, concentration in mg/mL; G, gel; N, number; NM, nitrogen mustard;
NR, no response or <50% improvement; O, ointment; OR, objective response.
N
g
u
ye
n
&
B
o
h
ja
n
e
n
6
8
6
Skin-Directed Therapies in CTCL 687disease; 158 of these patients applied topical nitro-
gen mustard ointment and 28 applied an aqueous
preparation of topical nitrogen mustard. Patients
either received total-body application if disease
was extensive or lesional application if disease
was limited as their initial and only treatment of
MF. By using only mechlorethamine, the investiga-
tors were able to show the true effect of nitrogen
mustard on disease management without influence
from other therapies. There was no statically signifi-
cant difference in efficacy or survival in patients
treated with ointment versus aqueous preparation.
The total response rate was 93% and 72% in stage
T1andT2disease, respectively.Of these, 65%ofT1
and 34% of T2 had a CR. Included in Kim and col-
leagues’ 2003 retrospective analysis was Price and
colleagues’38 1983 study (excluded from table), in
which 13 patients with stage IA/IB MF were treated
with nitrogen mustard ointment as initial therapy; 6
patients with stage 1A/1B MF as adjuvant to TSEB
(30–40Gy)within 4 to 8weeks of completion of radi-
ation39; and 12 patients with MF (stage unspecified)
in the setting of recurrent disease after clearance on
alternate therapies,who had never been exposed to
nitrogenmustard. Of 13patients treatedwith topical
nitrogen mustard as initial therapy, 69% had a CR
and 23% had a PR.When used as adjuvant therapy
after TSEB, of 6 patients, 100%hadCR. However, 1
patient developed recurrence, but later had partial
clearing with continued nitrogen mustard ointment
therapy. Of the 12 patients with recurrent disease
who had never been exposed previously to nitrogen
mustard, 5 patients (42%) had initial CR, although 1
developed recurrence during the evaluation period,
and another 42% had a PR. Price and colleagues’38
data show that nitrogen mustard ointment may be
beneficial in patients in multiple settings, including
as both adjuvant therapy andwith recurrent disease
inpatientswhohavenotpreviously beenexposed to
nitrogen mustard.
In 2013, the FDA approved the first mechloreth-
amine preparation for CTCL treatment in the form
of Valchlor,32 a topical gel based on the only
randomizedcontrolled trial todate inMFof a topical
medication. The study evaluated the efficacy of
0.02% topical mechlorethamine gel compared
with 0.02% topical compoundedmechlorethamine
ointment in stage IA and IBpatients.30 This phase II,
multicenter, randomized, observer-blinded, nonin-
feriority study found ORR rates of 58.5% and
47.7% by the Composite Assessment of Index
Lesion Severity (CAILS) where target lesion re-
sponses were assessed, and 46.9% and 46.2%
by the Modified Severity Weighted Assessment
Tool for gel compared with ointment, respectively.
CRs between the gel and ointment intent-to-treat
groups were not significantly different (18.9% vs14.7% respectively by CAILS in the efficacy-
evaluable population). In contrast, the average
time needed to achieve PR (50% improvement)
was significantly shorter (P<.01) with the gel
(26 weeks) compared with ointment (42 weeks).
However, the duration of clinical response was
not significantly different in the two treatment
groups. Patients enrolled in the studywere not initi-
ated on therapy until they went through a 4-week
washout period of therapies directed toward the
disease. Patients were excluded from the study if
they had ever received topical carmustine, if they
had received topical nitrogen mustard in the last
2 years, or if they had received irradiation in the
last year. Ninety-eight of the 260 patients in the
initial 0.02% topical nitrogen mustard trials partici-
pated in a phase II, open-label extension study for
an additional 6 months of 0.04%mechlorethamine
gel.40 Twenty-six of 98 (26.5%) patients achieved
at least a 50% reduction of their CAILS score
compared with that at the beginning of this
extension study with 6.1% CRs and 20.4% PRs,
indicating the possible benefit of additional use of
0.04% mechlorethamine gel in patients who fail to
clear with 0.02% mechlorethamine gel.
There have been many local adverse reactions
associated with topical mechlorethamine. Mild
irritant dermatitis, including pruritus, dysesthesias,
and eczematous reactions, are the most com-
mon.30,41 Hyperpigmentation has also been re-
ported in a large number of patients and is
reversible after drug cessation.30,42 One rare case
report documented anaphylaxis after application.43
The most common cause of therapy cessation is a
delayed allergic contact dermatitis that can range
frommild erythema to bullae formation.29,34–36,38,41
Irritant and allergic contact dermatitis have been
reported in up to 80% of patients treated with the
aqueous formulation, 29% with ointment, and
40% with the gel.30,37 However, therapy discontin-
uation can usually be prevented by application of
topical steroids, prior desensitization in the case
of an allergic contact dermatitis, or decreasing
the concentration of the medication or frequency
of application in cases of irritant dermatitis.31,42,44
A 2005 French study of 64 stage T1 and T2
patients with MF, revealed that combination treat-
ment with topical nitrogen mustard and topical ste-
roids could reduce adverse cutaneous reactions
and still be effective.41 Patients were treated with
twice-weekly 0.02% mechlorethamine aqueous
solution to the entire skin surface, excluding the
head. Within 10 minutes of application of nitrogen
mustard, up to 15 g of betamethasone cream was
applied. Only 33% of patients developed an
adverse cutaneous reaction but efficacy was com-
parable to that found in prior studies (see Table 1),
Nguyen & Bohjanen688with a CR of 58% in both the stage T1 and T2
groups.
In patients in whom local application of topical
steroids is not enough to control contact reactions,
desensitization may be required. Price’s44 study
showed that patients treated with electron beam
radiation as adjuvant therapy to aqueous nitrogen
mustard displayed a much lower rate of hypersen-
sitivity reactions (8% of 43 patients). In a follow-up
study, only 3 of 9 (33%) patients with prior hyper-
sensitivity to nitrogen mustard developed hyper-
sensitivity after receiving adjuvant electron beam
radiationwith nitrogenmustardointment therapy.38
None of the 16 patients without prior history of hy-
persensitivity treated in the same manner had an
adverse cutaneous reaction. It was hypothesized
that electron beam radiation depresses the immu-
nologic response, thus leading to a lower incidence
of cutaneous reactions. Thus, in patients with
concern for hypersensitivity reaction, the use of
adjuvant electron beam radiation may be useful in
suppressing hypersensitivity reactions.
In addition to electron beam radiation adjuvant
therapy, systemic mechlorethamine may also
be useful for desensitizing patients who are hy-
persensitive to topical nitrogen mustard.45 Von-
derheid and colleagues45 used desensitization
with once-weekly intravenous injections of 200 mg
of mechlorethamine over 4 to 5 weeks. However,
7 of 31 patients (22.5%) treated with systemic
desensitization developed linear dermatitis at the
site of administration. This adverse reaction and
the need for hospitalization to perform the desen-
sitization led to Vonderheid and colleagues45
favoring topical immunotherapy to systemic
desensitization. Topical immunotherapy for desen-
sitization was performed with either aqueous
mechlorethamine at 10, 1, or 0.1 mg in 0.1 mL of
water or aqueous dinitrochlorobenzene at 250,
25, or 2.5 mg dissolved in equal parts acetone and
water, which was then applied to 15 cm2 of normal
skin. Applications were observed at 48 hours and
repeated until a 21 reaction (erythema and vesicu-
lation) was observed. In some patients, application
to involved skin was performed to achieve a 31 re-
action (bullae formation and denudation). In 8 of 19
patients (42%), intentional induction of a delayed
hypersensitivity reaction led to CR, with another
42% showing PR in the degree of infiltration of
lesions. However, several patients developed
excessive pruritus, secondary skin infections, or
decreased sensitivity to topical mechlorethamine.
Given these side effects and the concern for
decreased response following immunotherapy, it
is recommended that further studies be performed
to evaluatemethods of decreasing hypersensitivity
reactions to topical nitrogen mustard.The long-term side effects of topical mechlor-
ethamine are controversial. There have been
reports of 1% to 5% increased risk of nonmela-
noma skin cancers.31,35,36,46–48 The largest of
these studies, by Vonderheid and colleagues,35
evaluated 331 patients treated with aqueous nitro-
gen mustard and 31 cases of squamous cell carci-
noma (relative risk, 7.8) and 27 cases of basal cell
carcinoma (relative risk, 1.8) were observed. How-
ever, a 30-year population-based cohort study
revealed no significantly increased risk of second-
ary cutaneous malignancy in 110 patients treated
with topical mechlorethamine for an average of
2.7 years (range, 2 days to 14.6 years), compared
with 193 patients not treated with mechloreth-
amine (hazard ratio, 0.84; 95% confidence inter-
val, 0.46–1.56).49 The study also did not find an
increased risk of comorbidities, including pulmo-
nary disease, in contrast with previous reports of
an increased risk of pulmonary cancer develop-
ment after inhalation of topical nitrogen
mustard.50,51
Studies suggest that topical application of nitro-
genmustard does not lead to systemic absorption.
In 203 patients treated with nitrogen mustard
ointment over a median of 5 years, Kim and col-
leagues’31 study found no abnormalities in com-
plete blood count or chemistries obtained every
2 to 3 months. Reinforcing this, Lessin and col-
leagues’30 2013 study, which led to FDA approval
of Valchlor, also revealed no hematologic or chem-
istry abnormalities in the 260 patients studied with
laboratory tests obtained at baseline, 4, 8, and
12 months. In addition, of 16 patients evaluated
with liquid chromatography at 0, 1, 3, and 6 hours
after application on day 1 and at week 4, there was
no detectable blood level of nitrogen mustard. This
finding suggests the relative safety of topical nitro-
gen mustard use. However, use in pregnancy
should be pursued only after extensive conver-
sation with the patient about Mustargen’s docu-
mented mutagenicity as a systemic agent and
the topical gel formulation classification as
pregnancy class D.52 The pregnancy classification
is based on rat data using 33-fold to 25-fold higher
doses than are used as standard for chemo-
therapy and that were administered in the first
weeks of gestation.53 In a 1976 study, Cytostasan
(a nitrogen mustard derivative) at high doses of
20 to 100 mg/kg was injected intraperitoneally
into pregnant rats at days 4, 7, 9, 11, and 13 post-
coitum, which led to many birth defects (kinked
tail, omphalocele, hydronephrosis, hydrocephaly).
In contrast, a case report of 2 pregnant women
with Hodgkin lymphoma treated with systemic
nitrogen mustard at a much lower dose of 0.4 to
0.6 mg/kg in the second trimester revealed no birth
Skin-Directed Therapies in CTCL 689defects,54 although 1 of the infants was born
prematurely at 7 months, resulting in jaundice,
hepatomegaly, and anemia. Further studies are
needed to evaluate the exact mechanism of
topical mechlorethamine and to determine its effi-
cacy and safety profile, especially when used in
combination with other therapies.
Ideally, treatment with topical nitrogen mustard
should start with once-daily application to lesional
skin in stage IA and total body surface in stage IB.
Patients should continue treatment for at least 3
to 6 months to assess response.40 For aqueous
preparations, 10-mg vials of mechlorethamine
should be mixed in 60 mL of water and immedi-
ately painted on the skin. Lower concentrations
should be used when patients show an allergic
or irritant reaction.31,33–36 Ointment preparations
are made by mixing 10 mg of Mustargen first
with 95% alcohol to remove the powder in
the vial and then in 100 g of Aquaphor (a nonpolar
and anhydrous vehicle with a low incidence
of sensitization) to a final concentration of
0.2 mg/mL, which can be applied once daily to
the whole body in generalized disease or to le-
sional skin in localized disease.31,37,38 It is recom-
mended that application of the medication should
occur on dry skin 4 hours before or 30 minutes af-
ter showering. Patients should also wash their
hands completely with soap and water after appli-
cation.52 Treatment with Valchlor has not been
evaluated in stage IIA patients but, based on
earlier studies with the extemporaneous com-
pounded nitrogen mustard preparations, is likely
to be effective.31,33–35 In general, although the
mechanism of action of topical nitrogen mustard
is unclear, it represents an efficacious option for
early stage MF with its use mainly limited by de-
layed contact hypersensitivity.Carmustine
Also known as bichlorethylnitrosourea (BCNU),
carmustine is an alkylating agent that undergoes
spontaneous degradation with the production of
electrophiles. Subsequently, DNA is alklyated
and cross-links.27
Similar to nitrogen mustard, BCNU can be
compounded in an aqueous or ointment formula-
tion: to date, there is no FDA-approved formula-
tion. Data on topical BCNU largely come from
the experience of Zackheim55 at the University
of California, San Francisco. In 1972, Zackheim55
first described the use of topical carmustine in
MF. In 1990, he published a retrospective study
on 87 patients treated with aqueous carmustine.56
A stock solution wasmade by dissolving 100mg of
carmustine into 50 mL of 95% ethanol to yield2 mg/mL. Patients applied 20 to 30 mL to deliver
40 to 60 mg per day for 2 to 3 weeks. If patients
developed bone marrow suppression, defined as
white blood cell count less than 4000 cells/mL,
the dose was decreased to 10 mg/d. To apply
10 mg/d, 10 mg (or 5 mL of stock solution) were
dissolved in 60 mL of warm water, producing a
concentration of 0.17 mg/mL. If treated with this
lower dose of 10 mg/d, patients were treated for
up to 17 weeks, median 7 to 14 weeks. In patients
who continued to have residual lesions after total-
body treatment, individual lesions were treated
with the higher-alcohol stock solutions of 2 to
4 mg/mL, limiting use to 70 mg/wk.56 Patients
who had an inadequate response to 10 mg/d
were given a 6-week rest period and then
retreated with 20 mg/d for 4 to 8 weeks. The study
showed a total response rate of 98% (CR, 86%;
PR, 12%) in stage T1 and 84% (CR, 47%; PR,
37%) in stage T2 patients.56 Compared with the
1987 study by the Stanford group,37 which evalu-
ated the use of topical mechlorethamine in 123
patients, the patients treated with topical car-
mustine had a much shorter period to CR. Mean
time to CR in the Stanford study was 12.9 months,
with a median of 7.9 months. In contrast, the
mean time to CR in Zackheim and colleagues’56
1990 study was 4.6 months with a median of
2.9 months. In comparison, mechlorethamine gel
takes average 6.5 months to achieve partial
remission,30 suggesting that perhaps topical car-
mustine is overlooked as a potential first-line
effective treatment of MF. However, there are
very few studies evaluating the efficacy of topical
carmustine and further randomized controlled
trials comparing topical carmustine and topical
nitrogen mustard are needed to further assess
this.
Myelosuppression represents the most con-
cerning adverse effect of topical carmustine, with
percutaneous absorption occurring up to 28% of
patients.57–60 Leukopenia as low as 2700 cells/
mm can be seen in 3.7% to 5.0% of patients
treated with BCNU 10 to 25 mg/daily for 3 to
17 weeks, although it typically appears after cu-
mulative BCNU dosing of 600 mg. Despite this,
there are no case reports of patients developing
opportunistic infections while being treating
with topical BCNU. More commonly, patients
show cutaneous reactions, including erythema,
telangiectasias, and hyperpigmentation.56,59–61
Biopsies of hyperpigmented skin reveal enlarged
melanocytes, but not an increased number of
melanocytes.61 Telangiectasias can resolve with
discontinuation of topical carmustine, although
they typically are permanent.57 Irritant and contact
dermatitis also may occur with topical BCNU, but
Nguyen & Bohjanen690less frequently (<10%) than with topical nitrogen
mustard.57,61 There have been no reported cases
of secondary or nonmelanoma skin cancer associ-
ated with topical BCNU.27,62
These potentially concerning side effects from
use of topical carmustine and its need to be
compounded limit its use. Studies have shown that
malignancies can circumvent the toxic effects of
BCNU through a DNA repair enzyme, O6-
alkylguanine DNA alkyltransferase (AGT).63,64 As
such, a 2012 open-label, dose-escalation, phase I
clinical trial attempted to use a drug,
O6-benzylguanine, to inhibit this DNA repair
enzyme. O6-benzylguanine is a guanine analogue
that inactivates AGT and prevents DNA repair.65 In
doing so, it may potentiate the effects of topical
BCNU in damaging DNA. By potentiating the
effects of topical BCNU, O6-benzylguanine may
enable a reduction of frequency of topical BCNU
application. The study treated 21 patientswith early
stage MF with topical aqueous BCNU following
intravenous administration of O6-benzylguanine.
Patients were treated less frequently with topical
BCNUatdosesof 10 to 40mg/d fromaconcentrate
of 3.33mg/mL applied once every 2weeks for up to
70 weeks compared with previously described
daily dosing. The study found an ORR of 76%
among all patients. Although this is lower than
reported in the previous study published by Zack-
heim,57 the investigators noted that their patients
may have been examples of more treatment-
refractory cases: the median time to treatment
following diagnosis of MF for their patients was
78 months compared with the 4 months in Zack-
heim’s57 study. The investigators reported a lower
rate of cutaneous reactions with application of
topical BCNU once every 2 weeks compared with
daily application (52% vs 100%) and 7.4% of their
patients developed leukopenia. In addition, 2 pa-
tients had mildly increased aspartate aminotrans-
ferase levels.
Although the limited retrospective studies of
topical BCNU use in the treatment of MF have
shown a good response, given the adverse effects
described earlier, its usage remains limited to
second-line and third-line treatment.62 Further
studies are needed to evaluate its efficacy and
systemic safety in MF.
In clinical practice, the aqueous compound is
prepared by dissolving 100 mg of BCNU in
50 mL of 95% ethanol to a stock concentration
of 2 mg/mL or 0.2%. This compound is stable in
the refrigerator for up to 3 months. Before topical
application, 5 mL (10 mg) of the stock solution
are then dissolved in 60 mL water to a concentra-
tion of 0.17 mg/mL. Patients paint a thin layer onto
the involved lesional skin once daily while wearinga pair of plastic gloves.56,66 Zackheim57 describes
preparation of BCNU ointment in his 2003 article,
but its use has never been described in any
studies. The ointment is made by taking 50 mL of
the 2 mg BCNU/mL ethanol stock solution and
mixing it with 100 g of petrolatum. This ointment
is applied in the same way as the aqueous
solution.56,57
We recommend using the aqueous compound,
at 10mg/60mL to the total-body surface area daily
for a maximum of 17 weeks.57 Typical dose dura-
tion should be limited to 6 to 8 weeks (cumulative
dose, 420–560 mg) to prevent adverse reactions.
Leukopenia is not usually seen at total doses less
than 600 mg and cutaneous side effects are not
usually seen until after 4 weeks of therapy at
10 mg/60 mL.66 If response is inadequate after
the first course, following a 6-week rest period, a
second course using 20 mg/60 mL can be applied
daily for up to 30 days. At the end of a total-body
course, localized lesions can be treated with the
2mg/mL stock solution, limited to 70mg/wk. Zack-
heim and colleagues66 recommendedmonitoring a
complete blood count every 2 to 4 weeks during
treatment and for 6 weeks after treatment. Before
and after complete metabolic panel (CMP) are
also advisable.RETINOIDS
Retinoids are a group of vitamin A–derived
compounds that are important in several biologi-
cal processes, most importantly, in the case of
CTCL, cellular differentiation, proliferation, and
apoptosis.67,68 These effects aremediated through
2 families of intracellular receptors: retinoic acid
receptors (RAR) and retinoid X receptors (RXR).
Each of these intracellular receptors has 3 major
subtypes (alpha, beta, gamma), each with multiple
different isoforms.69 Varying receptor subtypes
govern the biological effects of different reti-
noids, whether given systemically or topically. For
example, the effect of keratinocyte differentiation
by topical retinoids is controlled by RAR-a/RAR-g
heterodimers.70 The role of topical retinoids in MF
may be secondary to their ability to restore normal
cellular differentiation across the entire epithelia,
thus arresting carcinogenesis.71 The apoptotic
effect of retinoids may require both RAR and
RXR activity, with high concentrations (>1 mM) of
the FDA-approved RXR-specific retinoid (or rexi-
noid) bexarotene displaying some cross-
reactivation of RAR receptors and, subsequently,
cellular apoptosis.72,73 This function may be sec-
ondary to bexarotene’s effect on decreasing levels
of the protein survivin, an inhibitor of apoptosis that
has been found to be at increased levels in CTCL.74
Table 2
Other topical therapies for CTCL
Mechanism of Action Evidence for Use Dosing Adverse Events Additional Notes
Methotrexate-
laurocapram
Prevents DNA synthesis
through competitive
inhibition of
dihydrofolate reductase
Laurocapram is a lipophilic
compound
One published
retrospective study of 10
stage Ia/Ib patients with
MF86
Nine patients completed
study
Three of 9 (33%) had PR.
No patients had CR
12.5–25 g/m2 every
other day for 24 wk
with solution/oil
Pruritus, dryness,
erythema
Serum levels of
methotrexate
undetectable86
Has been shown to be
effective in psoriasis87
Calcineurin
inhibitors
Binding of calcineurin
inhibits
dephosphorylation of
nuclear factor of
activated T cells, leading
to decreased T-cell
activation, cytokine
release, and
downregulation of IgE
receptors
No studies
One case report of a 29-y-
old man with patch-
stage MF that responded
to 0.1% tacrolimus
ointment88
Twice daily for 1 mo
with tacrolimus 0.1%
ointment
None discussed Systemic use has been
associated with
increased incidence of
CTCL in
immunosuppressed
patients, although never
documented with
topical application88,89
Imiquimod Acts through TLR7 and
through unknown
mechanism leads to
cellular apoptosis
One open-label study of 6
patients with stage Ia–IIb
MF, PR 50%90
Case report of 4 patients
with stage Ia–IIb MF with
CR (1 also on IFNa-2a)91
Isolated case reports (total
7 patients with stage
Ia–IIb MF) with CR92–98
No standardized
method, although in
pilot study 3 times
per week for 12 wk
with 5% cream
Cutaneous reactions
of erythema,
pruritus, dysesthesias
and rarely ulceration,
bleeding, crusting
Pilot study did not show
clinical CR, but did have
histologic clearing in
50%90
When used in inguinal
region for genital warts
can have up to 1%
systemic absorption99
MF-like histology after
treating actinic keratoses
with imiquimod100
Abbreviations: IFNa, interferon alfa; IgE, immunoglobulin E; TLR7, Toll-like receptor 7.
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Nguyen & Bohjanen692However, the exact mechanism of topical retinoid
action in CTCL is unclear, especially because
systemic absorption of topical retinoids is minimal.
Two studies showed that application of topical
bexarotene 1% gel up to 4 times daily still resulted
in serum concentrations of less than 5 ng/mL in
80% to 95% of the 1074 specimens analyzed.75,76
In comparison, an oral dose of bexarotene
300mg/m2/d results in a serum drug concentration
of 1130  269 ng/mL.75Bexarotene
One-percent bexarotene gel (Targretin) was
approved for the treatment of refractory early
CTCL in 2000.77,78 Patients are generally instructed
to apply the 1% bexarotene gel to lesional skin
every other day. Frequency of dosing should then
increase to daily, twice daily, 3 times daily, and 4
times daily in 1-week intervals, as the patient is
able to tolerate.75,79
There have been 2 main studies evaluating the
efficacy of bexarotene 1% gel in MF. In a multi-
center, phase I/II study of 67 patients, an ORR of
63% was seen (CR, 21%; PR, 42%) with a median
onset to response of 12 to 20 weeks and time to
CR of 25 weeks.75 Remissions ranged from 12 to
21 weeks, but up to 5 years with maintenance
therapy. Most of these patients had previously
received other therapies for their MF. The 12
patients treated in this study, in which bexarotene
was the initial therapy for MF, had a slightly higher
ORR of 76%. To further evaluate the response rate
of refractory disease, a multicenter, phase III trial
of 50 patients showed an ORR of only 44% (CR,
8%).74 Refractory disease was defined in this
study as having failed (intolerant to or reached a
6-month plateau) of 2 different treatment op-
tions. There have also been case reports of the
efficacy of topical bexarotene in lymphomatoid
papulosis and folliculotropic MF.79,80Tazarotene
In contrast with bexarotene, tazarotene binds with
high affinity to RARs, most predominantly RAR-g
in the epidermis. Its use as a topical agent in MF
has been assessed in a single pilot study of 20
patients with treatment-refractory MF.81 Patients
applied 0.1% tazarotene gel once daily to lesional
skin, with 58% of patients experiencing greater
than a 50% improvement in index lesions but
no patients showing a CR. These patients were
allowed to use topical steroids concomitantly
with their treatment to reduce cutaneous irritation.
Thus, analysis of the clinical significance of this is
difficult.Alitretinoin
Alitretinoin is the only topical retinoid with both
RAR and RXR activity. It has been approved since
1999 for the treatment of Kaposi sarcoma, but has
not been evaluated in any complete study for the
treatment of MF.82–84 In the 1990s, 2 phase I/II
trials were performed to evaluate the effect of
topical bexarotene and topical alitretinoin in MF.
The study found that 7 patients had some
response to topical alitretinoin 0.1% gel with
twice-daily applications. However, the study was
terminated and continued evaluation of alitretinoin
gel was stopped in favor of topical bexarotene
given a lower adverse reaction profile and similar
efficacy rate.84 One case report in 2002 did show
complete resolution of tumor stage MF with
0.1% alitretinoin gel, applied daily for an unclear
duration.84
Adverse cutaneous reactions of all the topical
retinoids are similar, with the most frequent
symptoms being local dryness, burning, erythema,
and desquamation.75,76,82–84 Vesiculobullous
eruptions have also occurred with topical be-
xarotene use.85 Rarely, allergic contact dermatitis
occurs with topical retinoids.82,83 The topical
retinoids also carry a theoretic risk of teratoge-
nicity. However, 2 cases of women who conceived
while on topical tazarotene did not involve any
birth complications.85 Regardless, contraceptives
are recommended for women of childbearing age
using topical retinoids and the use of topical
retinoids should be avoided in pregnancy.
EMERGING TOPICAL THERAPIES
The remaining topical therapies mentioned in this
article for treatment in MF have not been exten-
sively studied (Table 2), only having been evalu-
ated in MF treatment over the last decade.
Imiquimod is noted for local use by the NCCN
guidelines. Most instances of their use have been
reported in case reports and further studies are
needed to validate their efficacy.
SUMMARY
Early stage MF represents the most common clin-
ical presentation of cutaneous lymphoma, with
skin-directed therapies long established in its
treatment. These therapies continue to change
as new treatment regimens emerge. Other skin-
directed therapies, such as light and radiation
therapy, are discussed by kelsey and Colleagues
elsewhere in this issue. Therapies with higher
levels of evidence and less systemic toxicity are
usually preferred as first-line treatment. However,
even these established therapies, like topical
Skin-Directed Therapies in CTCL 693corticosteroids and carmustine, lack randomized
clinical trials to establish their efficacy. Research
is also needed to further define the role of combi-
nation topical therapies and how skin-directed
therapies can be used as adjuvants to systemic
medications.REFERENCES
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